CN110655534A - Tenofovir lipid monoester compound and preparation method and application thereof - Google Patents
Tenofovir lipid monoester compound and preparation method and application thereof Download PDFInfo
- Publication number
- CN110655534A CN110655534A CN201910257106.2A CN201910257106A CN110655534A CN 110655534 A CN110655534 A CN 110655534A CN 201910257106 A CN201910257106 A CN 201910257106A CN 110655534 A CN110655534 A CN 110655534A
- Authority
- CN
- China
- Prior art keywords
- compound
- integer
- tenofovir
- tfv
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 79
- 229960004556 tenofovir Drugs 0.000 title claims abstract description 78
- -1 Tenofovir lipid Chemical class 0.000 title claims abstract description 35
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 9
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 8
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims description 96
- 239000003814 drug Substances 0.000 claims description 16
- 238000005660 chlorination reaction Methods 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 10
- 239000003513 alkali Substances 0.000 claims description 8
- 238000005886 esterification reaction Methods 0.000 claims description 8
- 238000006460 hydrolysis reaction Methods 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 241000700721 Hepatitis B virus Species 0.000 claims description 7
- 241000700605 Viruses Species 0.000 claims description 6
- NEOFIZRBXWOXNG-UHFFFAOYSA-N 3-(6-amino-7h-purin-2-yl)propan-1-ol Chemical compound NC1=NC(CCCO)=NC2=C1NC=N2 NEOFIZRBXWOXNG-UHFFFAOYSA-N 0.000 claims description 5
- 208000006454 hepatitis Diseases 0.000 claims description 5
- 231100000283 hepatitis Toxicity 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 230000000840 anti-viral effect Effects 0.000 claims description 4
- 239000012320 chlorinating reagent Substances 0.000 claims description 4
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- MEKOFIRRDATTAG-UHFFFAOYSA-N 2,2,5,8-tetramethyl-3,4-dihydrochromen-6-ol Chemical compound C1CC(C)(C)OC2=C1C(C)=C(O)C=C2C MEKOFIRRDATTAG-UHFFFAOYSA-N 0.000 claims description 3
- 230000032050 esterification Effects 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 239000012752 auxiliary agent Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003443 antiviral agent Substances 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 138
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 57
- 238000003756 stirring Methods 0.000 description 52
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 51
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 42
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 36
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 30
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
- 230000002829 reductive effect Effects 0.000 description 22
- SVUJNSGGPUCLQZ-FQQAACOVSA-N tenofovir alafenamide fumarate Chemical compound OC(=O)\C=C\C(O)=O.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1.O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 SVUJNSGGPUCLQZ-FQQAACOVSA-N 0.000 description 21
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 18
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 18
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000002904 solvent Substances 0.000 description 17
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 16
- 201000010099 disease Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 16
- IACQCQDWSIQSRP-ZCFIWIBFSA-N [(2r)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-[hydroxy(phosphonooxy)phosphoryl]oxyphosphinic acid Chemical compound N1=CN=C2N(C[C@@H](C)OCP(O)(=O)OP(O)(=O)OP(O)(O)=O)C=NC2=C1N IACQCQDWSIQSRP-ZCFIWIBFSA-N 0.000 description 15
- 238000001914 filtration Methods 0.000 description 15
- 210000004027 cell Anatomy 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 150000002148 esters Chemical class 0.000 description 14
- 239000012065 filter cake Substances 0.000 description 13
- 238000002386 leaching Methods 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 238000001816 cooling Methods 0.000 description 12
- 239000000203 mixture Substances 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000007787 solid Substances 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 10
- ITQTTZVARXURQS-UHFFFAOYSA-N 3-methylpyridine Chemical compound CC1=CC=CN=C1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 10
- FKNQCJSGGFJEIZ-UHFFFAOYSA-N 4-methylpyridine Chemical compound CC1=CC=NC=C1 FKNQCJSGGFJEIZ-UHFFFAOYSA-N 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 10
- 208000002672 hepatitis B Diseases 0.000 description 10
- 229940002612 prodrug Drugs 0.000 description 10
- 239000000651 prodrug Substances 0.000 description 10
- 229960001355 tenofovir disoproxil Drugs 0.000 description 10
- JFVZFKDSXNQEJW-CQSZACIVSA-N tenofovir disoproxil Chemical compound N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N JFVZFKDSXNQEJW-CQSZACIVSA-N 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000001035 drying Methods 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 229960004693 tenofovir disoproxil fumarate Drugs 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- 239000008096 xylene Substances 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 8
- 241000700159 Rattus Species 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 208000030507 AIDS Diseases 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
- 241000725303 Human immunodeficiency virus Species 0.000 description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- 210000000813 small intestine Anatomy 0.000 description 6
- MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 6
- KTVKQTNGWVJHFL-UHFFFAOYSA-N 2-ethylchromen-4-one Chemical compound C1=CC=C2OC(CC)=CC(=O)C2=C1 KTVKQTNGWVJHFL-UHFFFAOYSA-N 0.000 description 5
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 5
- 241000124008 Mammalia Species 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 210000003494 hepatocyte Anatomy 0.000 description 5
- 230000002503 metabolic effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 210000002700 urine Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 4
- JLTDJTHDQAWBAV-UHFFFAOYSA-N N,N-dimethylaniline Chemical compound CN(C)C1=CC=CC=C1 JLTDJTHDQAWBAV-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 159000000000 sodium salts Chemical class 0.000 description 4
- VDZOOKBUILJEDG-UHFFFAOYSA-M tetrabutylammonium hydroxide Chemical compound [OH-].CCCC[N+](CCCC)(CCCC)CCCC VDZOOKBUILJEDG-UHFFFAOYSA-M 0.000 description 4
- WGTYBPLFGIVFAS-UHFFFAOYSA-M tetramethylammonium hydroxide Chemical compound [OH-].C[N+](C)(C)C WGTYBPLFGIVFAS-UHFFFAOYSA-M 0.000 description 4
- 239000003039 volatile agent Substances 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102100032534 Adenosine kinase Human genes 0.000 description 3
- 108020000543 Adenylate kinase Proteins 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 description 3
- 235000010216 calcium carbonate Nutrition 0.000 description 3
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 3
- 239000000920 calcium hydroxide Substances 0.000 description 3
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 3
- 229940011051 isopropyl acetate Drugs 0.000 description 3
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 3
- 239000000347 magnesium hydroxide Substances 0.000 description 3
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 3
- ORPJQHHQRCLVIC-UHFFFAOYSA-N magnesium;propan-2-olate Chemical compound CC(C)O[Mg]OC(C)C ORPJQHHQRCLVIC-UHFFFAOYSA-N 0.000 description 3
- 238000004949 mass spectrometry Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 231100000417 nephrotoxicity Toxicity 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 description 3
- 239000011736 potassium bicarbonate Substances 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 235000011181 potassium carbonates Nutrition 0.000 description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 3
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- BUNLUJOOYFRECC-UHFFFAOYSA-N 1-hexadecoxyethanol Chemical compound CCCCCCCCCCCCCCCCOC(C)O BUNLUJOOYFRECC-UHFFFAOYSA-N 0.000 description 2
- CSDQQAQKBAQLLE-UHFFFAOYSA-N 4-(4-chlorophenyl)-4,5,6,7-tetrahydrothieno[3,2-c]pyridine Chemical compound C1=CC(Cl)=CC=C1C1C(C=CS2)=C2CCN1 CSDQQAQKBAQLLE-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- 108090000371 Esterases Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical group [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- 230000007073 chemical hydrolysis Effects 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- 239000012046 mixed solvent Substances 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940073455 tetraethylammonium hydroxide Drugs 0.000 description 2
- LRGJRHZIDJQFCL-UHFFFAOYSA-M tetraethylazanium;hydroxide Chemical compound [OH-].CC[N+](CC)(CC)CC LRGJRHZIDJQFCL-UHFFFAOYSA-M 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 206010019842 Hepatomegaly Diseases 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101001122938 Homo sapiens Lysosomal protective protein Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 102100028524 Lysosomal protective protein Human genes 0.000 description 1
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
- YVFXEROXSBNITE-UHFFFAOYSA-N N(=NC(=O)O)C(=O)O.C(C)(C)C=1C(=C(C=CC1)P(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C Chemical compound N(=NC(=O)O)C(=O)O.C(C)(C)C=1C(=C(C=CC1)P(C1=CC=CC=C1)C1=CC=CC=C1)C(C)C YVFXEROXSBNITE-UHFFFAOYSA-N 0.000 description 1
- XWBABSILBAABOK-UHFFFAOYSA-N N(=NC(=O)O)C(=O)O.C(C)C=1C(=C(C=CC1)P(C1=CC=CC=C1)C1=CC=CC=C1)CC Chemical compound N(=NC(=O)O)C(=O)O.C(C)C=1C(=C(C=CC1)P(C1=CC=CC=C1)C1=CC=CC=C1)CC XWBABSILBAABOK-UHFFFAOYSA-N 0.000 description 1
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 1
- SUAKHGWARZSWIH-UHFFFAOYSA-N N,N‐diethylformamide Chemical compound CCN(CC)C=O SUAKHGWARZSWIH-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010029155 Nephropathy toxic Diseases 0.000 description 1
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- YLEQMGZZMCJKCN-NKWVEPMBSA-N [[(2r,5s)-5-(4-amino-2-oxopyrimidin-1-yl)-1,3-oxathiolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)SC1 YLEQMGZZMCJKCN-NKWVEPMBSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 125000002015 acyclic group Chemical group 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002431 foraging effect Effects 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000003402 intramolecular cyclocondensation reaction Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 230000007694 nephrotoxicity Effects 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 229940086066 potassium hydrogencarbonate Drugs 0.000 description 1
- BYTCDABWEGFPLT-UHFFFAOYSA-L potassium;sodium;dihydroxide Chemical compound [OH-].[OH-].[Na+].[K+] BYTCDABWEGFPLT-UHFFFAOYSA-L 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 210000000512 proximal kidney tubule Anatomy 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000004885 tandem mass spectrometry Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960004946 tenofovir alafenamide Drugs 0.000 description 1
- LDEKQSIMHVQZJK-CAQYMETFSA-N tenofovir alafenamide Chemical compound O([P@@](=O)(CO[C@H](C)CN1C2=NC=NC(N)=C2N=C1)N[C@@H](C)C(=O)OC(C)C)C1=CC=CC=C1 LDEKQSIMHVQZJK-CAQYMETFSA-N 0.000 description 1
- 229960003560 tenofovir alafenamide fumarate Drugs 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Oncology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A tenofovir lipid monoester compound shown as a compound (1) or a pharmaceutically acceptable salt thereof,
Description
Technical Field
The invention relates to the field of chemical pharmacy, in particular to a tenofovir lipid monoester compound and a preparation method and application thereof.
Background
Tenofovir (TFV) is an acyclic nucleoside reverse transcriptase inhibitor with the strongest activity for resisting hepatitis B virus and HIV so far. Since the phosphonic acid in tenofovir is highly negatively charged under physiological acid-base conditions, it has the defects of poor intestinal tract penetration, poor cell penetration, limited distribution of target tissues, short plasma half-life, poor oral bioavailability, great toxic and side effects of the renal gastrointestinal tract and the like, thereby limiting the therapeutic effect of tenofovir on diseases.
Tenofovir Disoproxil Fumarate (TDF, US005935946A1), a prodrug of Tenofovir, has been marketed in 2001 for the treatment of hepatitis B and AIDS, and its antiviral component is Tenofovir. The tenofovir disoproxil fumarate is sequentially subjected to the following steps: (a) absorption into plasma by small intestine, (b) blood circulation into hepatitis B/AIDS target cells, (c) conversion to tenofovir by esterase hydrolysis and chemical hydrolysis, (d) phosphorylation of adenylate kinase to tenofovir monophosphate (TFV-MP), (e) further phosphorylation of nucleotide kinase to tenofovir diphosphate (TFV-DP) which can inhibit hepatitis B/AIDS virus, and exerting its therapeutic effect. (the metabolic mechanism is shown in FIG. 1).
The charge on the phosphonic acid in tenofovir is shielded in TDF, and the introduction of the ester increases the lipid solubility of the medicament, so that the penetrating power of the medicament on intestinal cell membranes is improved, and the oral bioavailability of the medicament is correspondingly improved. However, the structural modification is still not satisfactory clinically, for example, the structural modification has certain renal toxicity, large oral dose (150-300 mg), low bioavailability, liver enlargement caused by long-term administration, osteoporosis and the like. The bioavailability of the oral tenofovir disoproxil fumarate for dogs can reach 30 percent, the bioavailability of the oral tenofovir disoproxil fumarate for people is only 25 percent, and the bioavailability is influenced by food. The main reason is that ester hydrolase is widely distributed in vivo, so that the precursor drug of tenofovir disoproxil is mostly hydrolyzed into tenofovir with high negative charge before reaching hepatitis B/AIDS target cells. Tenofovir itself is not readily transported to target cells, but is actively transported to the proximal tubule of the kidney, resulting in some nephrotoxicity and poor oral bioavailability.
Tenofovir Alafenamide (Tenofovir Alafenamide Fumarate, TAF, WO2013116720a1), another prodrug of Tenofovir, has been marketed in 2016 for the treatment of hepatitis b and aids in 11 months. Unlike TDF, the metabolic mechanism of the liver-targeting pro-drugs of TAF is in turn: (a) absorption into plasma in the small intestine, (b) circulation of blood into hepatitis b/aids target cells, (c) hydrolysis of the carboxyl ester bond by serine protease cathepsin-a (a lysosomal enzyme with deamidase, esterase and carboxypeptidase activities), removal of isopropanol to release metastable metabolites, followed by intramolecular cyclization to remove phenolic groups, hydrolysis to tenofovir-alanine conjugate (TFV-Ala), (d) enzymatic chemical hydrolysis of the in vivo phosphoramidite to remove alanine to tenofovir, (e) phosphorylation of adenylate kinase to tenofovir monophosphate (TFV-MP), (f) further phosphorylation of nucleotide kinase to tenofovir diphosphate (TFV-DP) which inhibits hepatitis b/aids virus.
TAF is a liver-targeting highly potent prodrug of tenofovir. Clinically it is also easier to absorb in the small intestine than TDF, is stable in plasma, and 25 mg TAF exerts equivalent efficacy to 300mg TDF, only one-tenth the molar dose of TDF. The intake of small dose reduces the systemic exposure dose of tenofovir, thereby reducing the adverse reaction of kidney and bone.
Tenofovir lipid prodrug (Tenofovir mono-hexadecyloxypropy ester, HDP-TFV, WO2011100698A2) is another liver-targeting highly potent prodrug of Tenofovir and is currently in phase II clinical studies. The metabolic mechanism is that: (a) the small intestine absorbs into plasma, (b) the blood circulates into hepatitis B/AIDS target cells, (C) phosphoesterase-C promotes hydrolysis to obtain tenofovir, (d) adenylate kinase is phosphorylated into tenofovir monophosphate (TFV-MP), and (e) nucleotide kinase is further phosphorylated into tenofovir diphosphate (TFV-DP) capable of inhibiting hepatitis B/AIDS virus.
The lipid prodrug HDP-TFV of tenofovir is used for delivering drugs to the liver by utilizing a natural lipid uptake pathway. Clinically it is also easier to absorb in the small intestine, plasma stable and safe and effective than TAF, and 25 mg HDP-TFVF can exert equivalent efficacy to 300mg TDF, only one twelfth molar dose of TDF.
Another lipid prodrug HDDSB-TFV (Tenofovir mono-heptadecyldisfanylbutyl ester, J.Med.chem.2016,59,10244-10252) of Tenofovir contains disulfide bond reduction sensitive lipid, so far, has effective anti-hepatitis B/AIDS virus activity, has the best therapeutic index which is more than one hundred thousand, and is expected to become a new generation of lipid prodrug of Tenofovir.
The structures of the compounds TFV, TDF, TAF, HDP-TFV and HDDSB-TFV are shown as follows:
disclosure of Invention
The invention aims to provide a tenofovir lipid monoester compound shown as a compound (1) or a pharmaceutically acceptable salt thereof,
wherein X is selected from O, S or SS;
when X is selected from O, s is selected from an integer of 2-10, r is selected from an integer of 2-5, and t is selected from an integer of 0-17;
when X is selected from S, S is selected from an integer of 1-10, r is selected from an integer of 2-5, and t is selected from an integer of 0-17;
when X is selected from SS, s is selected from an integer of 1-10, r is selected from 3, and t is selected from an integer of 0-17.
According to an embodiment of the invention, in the compound (1), X is selected from O or SS;
when X is selected from O, s is selected from an integer of 2-4, r is selected from an integer of 2-3, and t is selected from an integer of 10-15;
when X is selected from SS, s is selected from an integer of 1-4, r is selected from 3, and t is selected from an integer of 10-15;
the pharmaceutically acceptable salt is selected from NH4Na, K, Ca or Mg salts.
As an example, the compound (1) is selected from the group consisting of,
as an example, the pharmaceutically acceptable salt of the compound (1) is selected from the group consisting of a compound,
the present invention also provides a process for producing the compound (1), comprising:
scheme 1:
1) chlorination: mixing Tenofovir (TFV), a chlorination aid and a chlorinating agent, and reacting to obtain a compound (3), wherein the chlorination aid is HCONR1 2，R1Are the same or different and are selected from C1-6Alkyl (e.g., methyl, ethyl);
2) esterification: carrying out esterification reaction on the compound (3) and ROH, and then carrying out hydrolysis reaction in the presence of acid to obtain a compound (1);
or
Scheme 2:
reacting tenofovir with a compound (6) to obtain a compound (1);
or
Scheme 3:
reacting tenofovir with a compound (7) to obtain a compound (1);
or
Scheme 4:
reacting hydroxypropyl adenine (HPA) with a compound (8), and performing acidolysis to obtain a compound (1);
wherein R is selected from [ (CH)2)rX]s(CH2)tCH3R, X, s, t have the definitions stated above;
y is selected from Cl, Br, I, MsO, TsO or TfO;
z is selected from MsO, TsO or TfO.
According to the preparation method of the present invention, in scheme 1,
the temperature of the chlorination step is-20-100 ℃, and preferably 0-50 ℃;
in a preferred technical scheme of the invention, the chlorination reaction is carried out in a solvent, wherein the solvent can be any one of or a combination of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane and 1, 2-dichloroethane;
in a preferred technical scheme of the invention, the chlorination aid in the chlorination step can be any one or combination of N, N-dimethylformamide and N, N-diethylformamide;
in a preferred technical scheme of the invention, the chlorinating agent in the chlorination step can be any one of oxalyl chloride and thionyl chloride or a combination thereof;
in the preferred technical scheme, the mol ratio of tenofovir to the chlorination auxiliary to the chlorinating agent in the chlorination step is 1: 1-5: 1-10; preferably 1: 1-2: 3-6;
in the preferred technical scheme of the invention, the temperature of the esterification reaction is-20-100 ℃, and preferably 0-50 ℃;
in a preferred technical scheme of the invention, the esterification reaction is carried out in a solvent, wherein the solvent can be any one or combination of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane and 1, 2-dichloroethane;
in the preferred technical scheme of the invention, the esterification reaction is carried out in the presence of alkali, and the alkali can be any one or the combination of triethylamine, N-diisopropylethylamine, N-methylmorpholine, pyridine, N-dimethylaminopyridine, 2, 6-dimethylpyridine and N, N-dimethylaniline;
in the preferable technical scheme of the invention, the molar ratio of the compound (3) in the esterification step to ROH to alkali is 1: 1-5: 1-10; preferably 1: 1-2: 1-5;
in the preferred technical scheme of the invention, the temperature in the acidolysis step is-20-100 ℃, and preferably 0-50 ℃;
in a preferred embodiment of the present invention, the acidolysis step is performed in a solvent, wherein the solvent may be any one or a combination of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, isopropyl ether, methanol, ethanol, isopropanol, and water;
in a preferred technical scheme of the invention, the acid used in the acidolysis step can be any one or the combination of formic acid, acetic acid, hydrochloric acid, sulfuric acid and phosphoric acid;
in a preferable technical scheme of the invention, the molar ratio of the compound (4) to the acid in the acidolysis step is 1: 1-50; preferably 1: 10-20;
according to the preparation method of the present invention, in scheme 2,
the reaction temperature is-20 ℃ to 100 ℃, and preferably 0 ℃ to 90 ℃;
the reaction is carried out in a solvent which can be one, two or more of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, N-dimethylformamide, N-diethylformamide, pyridine, 2-methylpyridine, 3-methylpyridine, 4-methylpyridine, 2, 6-dimethylpyridine, dimethylsulfoxide;
the reaction is carried out in the presence of a dehydrating agent which may be one, two or more of N, N, -dicyclohexylcarbodiimide, N, -diisopropylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, diethyl triphenylphosphine-azodicarboxylate, diisopropyl triphenylphosphine-azodicarboxylate, di-tert-butyl triphenylphosphine-azodicarboxylate;
the mol ratio of the tenofovir to the compound (6) to the dehydrating agent is 1: 1-5: 1-10; preferably 1:1 to 2:1 to 5.
In the process according to the invention, in scheme 3,
the reaction is preferably carried out in an inert gas atmosphere, for example in a nitrogen atmosphere;
the reaction temperature is-20 ℃ to 120 ℃, and preferably 0 ℃ to 100 ℃;
the reaction is carried out in a solvent which may be one, two or more of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, N-dimethylformamide, N-diethylformamide, pyridine, 2-methylpyridine, 3-methylpyridine, 4-methylpyridine, 2, 6-dimethylpyridine, dimethylsulfoxide;
the reaction is carried out in the presence of a base, which may be one, two or more of magnesium isopropoxide, magnesium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride, calcium hydride, tetramethylammonium hydroxide, tetraethylammonium hydroxide, tetrabutylammonium hydroxide, pyridine, 2-methylpyridine, 3-methylpyridine, 4-methylpyridine, 2, 6-dimethylpyridine, 4-dimethylaminopyridine, N-dimethylaniline, aqueous ammonia;
in the reaction, the molar ratio of tenofovir to the compound (7) to the alkali is 1: 1-5: 1-10; preferably 1:1 to 2:1 to 5.
According to the preparation method of the present invention, in scheme 4,
the reaction temperature is-20 ℃ to 100 ℃, and preferably 0 ℃ to 80 ℃;
the reaction is carried out in a solvent which can be one, two or more of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, N-dimethylformamide, N-diethylformamide, pyridine, 2-methylpyridine, 3-methylpyridine, 4-methylpyridine, 2, 6-dimethylpyridine, dimethylsulfoxide;
the reaction is carried out in the presence of a base, and the base used in the reaction may be one, two or more of magnesium isopropoxide, magnesium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide, lithium hydroxide, sodium hydroxide potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, calcium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, sodium hydride, calcium hydride, tetramethylammonium hydroxide, tetraethylammonium hydroxide, tetrabutylammonium hydroxide, pyridine, 2-methylpyridine, 3-methylpyridine, 4-methylpyridine, 2, 6-dimethylpyridine, 4-dimethylaminopyridine, N-dimethylaniline and aqueous ammonia.
In the reaction, the molar ratio of the hydroxypropyl adenine to the compound (8) to the alkali is 1: 1-5: 1-10; preferably 1:1 to 2:1 to 5.
According to the present invention, the method further comprises purifying the compound (1) obtained in any one of the schemes 1 to 4, for example, by crystallization, and specifically comprises: dissolving the product in a solvent, heating for dissolving, slowly cooling, and filtering to obtain a pure product of the compound (1).
In the preferred technical scheme of the invention, the heating and dissolving temperature in the purification step is-20-150 ℃, and the preferred temperature is-5-100 ℃;
in a preferred embodiment of the present invention, the solvent used in the purification step may be any one or two or more of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, ethyl acetate, isopropyl acetate, methyl tert-butyl ether, isopropyl ether, methanol, ethanol, and isopropanol, for example, a mixture solvent of methanol and dichloromethane.
The present invention also provides a process for producing a pharmaceutically acceptable salt of compound (1), which comprises:
and (2) carrying out neutralization reaction on the compound (1) and alkali to obtain a pharmaceutically acceptable salt of the compound (1).
In the preferred technical scheme of the invention, the temperature of the neutralization reaction is-20-100 ℃, and preferably 0-50 ℃;
in a preferred embodiment of the present invention, the solvent used in the neutralization reaction may be one, two or more of toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, methanol, ethanol, and isopropanol;
in a preferred technical scheme of the invention, the base in the salt forming step can be one, two or more of magnesium isopropoxide, magnesium tert-butoxide, sodium tert-butoxide, potassium tert-butoxide, sodium methoxide, sodium ethoxide, lithium hydroxide, sodium hydroxide, potassium hydroxide, magnesium hydroxide, calcium hydroxide, sodium carbonate, potassium carbonate, cesium carbonate, calcium carbonate, sodium bicarbonate, potassium bicarbonate, sodium hydride and ammonia water;
in the preferable technical scheme, the molar ratio of the compound (1) to the alkali in the salt forming step is 1: 1-5; preferably 1: 1.
The method also comprises the step of purifying the obtained product after salification, wherein the purification step comprises the following steps: dissolving the product in solvent 1, heating to dissolve, adding solvent 2 which is difficult to dissolve the product, and filtering to obtain pure product of pharmaceutically acceptable salt of compound (1).
In the preferred technical scheme of the invention, the temperature of the purification step is-20-150 ℃, and the preferred temperature is-5-100 ℃;
in a preferred embodiment of the present invention, the solvent 1 in the purification step is selected from one, two or more of methanol, ethanol and isopropanol;
the solvent 2 is one or two or more selected from acetone, toluene, xylene, tetrahydrofuran, 2-methyltetrahydrofuran, dioxane, ethylene glycol dimethyl ether, dichloromethane, 1, 2-dichloroethane, ethyl acetate, isopropyl acetate, methyl tert-butyl ether and isopropyl ether.
The invention also provides application of the compound (1) and/or pharmaceutically acceptable salt thereof in preparing antiviral drugs.
Preferably, the virus is hepatitis B virus and/or HIV.
The present invention also provides a pharmaceutical composition comprising compound (1) and/or a pharmaceutically acceptable salt thereof.
Preferably, the pharmaceutical composition is used for treating hepatitis B and/or AIDS.
The pharmaceutical composition optionally further comprises an adjuvant.
The present invention also provides a method for treating hepatitis B and/or AIDS, comprising administering to a subject in need thereof an effective amount of the above pharmaceutical composition.
Advantageous effects
The compound (1) or the pharmaceutically acceptable salt thereof provided by the invention is a better liver-targeting tenofovir lipid monoester prodrug, and the drug can be quickly absorbed by small intestine after entering the body and selectively metabolized into the antiviral tenofovir in the liver. Can reduce the distribution, accumulation and systemic circulation level of tenofovir in blood, tissues and kidney, and avoid renal toxicity and possible osteoporosis.
Definition and description of terms
Unless otherwise indicated, the numerical ranges set forth in the specification and claims are equivalent to at least each and every specific integer numerical value set forth therein. For example, a numerical range of "1 to 10" is equivalent to reciting each integer value in the numerical range of "1 to 10," i.e., 1,2, 3, 4, 5, 6, 7, 8, 9, 10. It is to be understood that "more" in one, two, or more of the substituents used herein when describing substituents shall mean an integer ≧ 3, such as 3, 4, 5, 6, 7, 8, 9, or 10.
The term "pharmaceutical composition" as used herein refers to a biologically active compound optionally mixed with at least one pharmaceutically acceptable chemical ingredient including, but not limited to, carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and/or excipients.
As used herein, reference to the term "subject" refers to subjects suffering from a disease, disorder or condition, and the like, including mammals and non-mammals. Examples of mammals include, but are not limited to, any member of the class mammalia: humans, non-human primates (e.g., chimpanzees and other apes and monkeys); livestock, such as cattle, horses, sheep, goats, pigs; domestic animals such as rabbits, dogs, and cats; laboratory animals, including rodents, such as rats, mice, and guinea pigs, and the like. Examples of non-human mammals include, but are not limited to, birds, fish, and the like. In one embodiment related to the methods and compositions provided herein, the mammal is a human.
As used herein, the term "treating" and other similar synonyms include alleviating, or ameliorating a symptom of a disease or disorder, preventing other symptoms, ameliorating, or preventing an underlying metabolic cause of a symptom, inhibiting a disease or disorder, e.g., arresting the development of a disease or disorder, alleviating a disease or disorder, ameliorating a disease or disorder, alleviating a symptom of a disease or disorder, or discontinuing a symptom of a disease or disorder, and further, the term encompasses prophylactic purposes. The term also includes obtaining a therapeutic effect and/or a prophylactic effect. The therapeutic effect refers to curing or ameliorating the underlying disease being treated. In addition, a cure or amelioration of one or more physiological symptoms associated with the underlying disease is also a therapeutic effect, e.g., an improvement in the condition of the patient is observed, although the patient may still be affected by the underlying disease. For prophylactic effect, the composition can be administered to a patient at risk of developing a particular disease, or to a patient presenting with one or more physiological symptoms of the disease, even if a diagnosis of the disease has not yet been made.
The term "effective amount" as used herein refers to an amount of at least one agent or compound sufficient to alleviate to some extent one or more of the symptoms of the disease or condition being treated upon administration. The result may be a reduction and/or alleviation of signs, symptoms, or causes, or any other desired change in a biological system. For example, an "effective amount" for treatment is the amount of a composition comprising a compound disclosed herein that is clinically necessary to provide a significant remission effect of the condition. An effective amount suitable in any individual case can be determined using techniques such as a dose escalation assay.
The invention obtains a hydrogen spectrum (1HNMR), phosphorus spectrum (31PNMR) data was obtained using a 400MHz nuclear magnetic resonance instrument (bruker advance II 400MHz) from bruker. Tetramethylsilicon (TMS) was used as an internal standard and collected at room temperature. Chemical shifts (δ) are parts per million (ppm). The singlet is denoted as s, the doublet as d, the triplet as t, the quartet as q, the multiplet as m and the broad singlet as brs. The coupling constant is denoted as j in Hz. The deuterated solvent is deuterated chloroform (CDCl)3) Or deuterated dimethyl sulfoxide (DMSO-d)6)。
The instrument used to obtain Mass Spectrometry (MS) data in this invention is Shimadzu LC 2010EV, forward, giving the ion peak of molecular weight hydrogenation (MH)+)。
Unless otherwise indicated, when the present invention relates to percentages between liquids, said percentages are volume/volume percentages; the invention relates to the percentage between liquid and solid, said percentage being volume/weight percentage; the invention relates to the percentages between solid and liquid, said percentages being weight/volume percentages; the balance being weight/weight percent.
Drawings
FIG. 1 is a diagram of the metabolic mechanism of several compounds.
Detailed Description
The technical solution of the present invention will be further described in detail with reference to specific embodiments. The following examples are merely illustrative and explanatory of the present invention and should not be construed as limiting the scope of the invention. All the technologies realized based on the above-mentioned contents of the present invention are covered in the protection scope of the present invention.
Unless otherwise indicated, the raw materials and reagents used in the following examples are all commercially available products or can be prepared by known methods.
Example 1Preparation of tenofovir mono (hexadecyloxyethoxyethoxyethyl) ester (HDEE-TFV)
1) Under the protection of nitrogen and the stirring at 15-25 ℃, slowly dripping 120 ml of oxalyl chloride into a mixture consisting of 100 g of Tenofovir (TFV), 50 g of N, N-dimethylformamide and 1L of dichloromethane, stirring and refluxing for 4-6 hours, and cooling to room temperature; concentrating under reduced pressure at 50 deg.C to remove volatile, adding 1L dichloromethane to dissolve residue;
2) slowly dripping a mixed solution of 125 g of Hexadecyloxyethanol (HDEE), 200 ml of triethylamine and 500 ml of dichloromethane into the dichloromethane solution obtained in the step 1) under the protection of nitrogen and the stirring at 0-10 ℃, stirring for 4 hours at room temperature, and concentrating under reduced pressure at 50 ℃ to remove volatile matters; adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 5 hours;
3) the layers were allowed to settle, the aqueous layer was extracted with 200 ml ethyl acetate, adjusted to pH 3 with 35% sodium hydroxide and the aqueous layer was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 180 g of tenofovir lipid monoester (HDEE-TFV) as white solid.
The characterization results of HDEE-TFV are shown below.
δ(1HNMR,DMSO-d6):0.86-0,92(m,3H),1.22(d，J＝7.5Hz，3H),1,24-1,33(m,26H),1.45-1,63(m,2H),3.40-3,67(m,6H),3.68-3.77(m,2H),3.77-3.88(m,2H),3.96(dd,J＝4.0,8,0Hz,1H),4.09-4.28(m,3H),4.28-4.33(m,1H),6,80(brs,3H),8.04(s,1H),8.16(s,1H)ppm；MS:600(M+H)。
Example 2Preparation of tenofovir mono (hexadecyloxyethoxyethoxyethyl) ester (HDEE-TFV)
1) Under anhydrous and anaerobic conditions, a mixture consisting of 100 g of Tenofovir (TFV), 125 g of Hexadecyloxyethanol (HDEE), 110 g of N, N, -dicyclohexylcarbodiimide and 600 ml of pyridine is stirred at 90 ℃ for 18 hours and then cooled to room temperature; filtering, leaching filter cakes by using dichloromethane, and concentrating the combined filtrate at 60 ℃ under reduced pressure to remove volatile matters;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) standing for layering, extracting the water layer with 200 ml ethyl acetate, and adjusting pH to 3 with 35% sodium hydroxide; the aqueous phase was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 185 g of tenofovir disoproxil fumarate lipid monoester (HDEE-TFV) as a white solid.
Example 3Preparation of tenofovir mono (hexadecyloxyethoxyethoxyethyl) ester (HDEE-TFV)
1) A mixture of 100 g Tenofovir (TFV), 20 g sodium hydroxide and 500 ml N, N-dimethylformamide was stirred at room temperature for 3 hours and concentrated at 80 ℃ under reduced pressure to remove volatiles; adding 500 ml of N, N-dimethylformamide and 150 g of hexadecyloxyethoxyethanol methanesulfonate (HDEEMs), stirring at 100 ℃ for 18 hours under the protection of nitrogen, and cooling to room temperature; then, the volatile matter was removed by concentration under reduced pressure at 80 ℃;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) standing for layering, extracting the water layer with 200 ml ethyl acetate, and adjusting pH to 3 with 35% sodium hydroxide; the aqueous phase was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 183 g of tenofovir disoproxil fumarate lipid monoester (HDEE-TFV) as a white solid.
Example 4Preparation of tenofovir mono (hexadecyloxyethoxyethoxyethyl) ester (HDEE-TFV)
1) A mixture of 68 g of hydroxypropyl adenine (HPA), 220 g of HDEEPTs, 30 g of magnesium tert-butoxide and 500 ml of N, N-dimethylformamide was stirred at 80 ℃ for 6 hours, and then concentrated under reduced pressure to remove volatiles;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) standing for layering, extracting the water layer with 200 ml ethyl acetate, and adjusting pH to 3 with 35% sodium hydroxide; the aqueous phase was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 188 g of tenofovir lipid monoester (HDEE-TFV) as white solid.
Example 5Preparation of tenofovir disoproxil (hexadecyldithiopropyl) ester (HDDSP-TFV)
1) Under the protection of nitrogen and the stirring at 15-25 ℃, 120 ml of oxalyl chloride is slowly dripped into a mixture consisting of 100 g of Tenofovir (TFV), 50 g of N, N-dimethylformamide and 1L of dichloromethane, stirred and refluxed for 4 hours, and then cooled to room temperature; concentrating under reduced pressure at 50 deg.C to remove volatile, adding 1L dichloromethane to dissolve residue;
2) under the protection of nitrogen and the stirring at 0-10 ℃, slowly dropwise adding a mixed solution of 130 g of hexadecyl dithio propanol (HDDSP), 200 ml of triethylamine and 500 ml of dichloromethane into the dichloromethane solution obtained in the step (1), stirring at room temperature for 4 hours, and concentrating under reduced pressure at 50 ℃ to remove volatile matters; adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 5 hours;
3) the layers were allowed to settle, the aqueous layer was extracted with 200 ml ethyl acetate, adjusted to pH 3 with 35% sodium hydroxide and the aqueous layer was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 185 g of tenofovir disoproxil fumarate lipid monoester (HDDSP-TFV) as a white solid.
Characterization data for HDDSP-TFV are shown below.
δ(1HNMR,DMSO-d6):0.84-0.94(m,3H),1.32(d，J＝7.5Hz，3H),1.23-1.54(m,25H)，1.62-1.72(m,2H),1.89-1,99(m,2H),2.55-2,70(m,4H),3.44-3.60(m,2H),3.93(dd,J＝4.0,8,0Hz,1H),4.06-4.24(m,3H),4.28-4.38(m,1H),6,83(brs,3H),8.06(s,1H),8.18(s,1H)ppm；MS:618(M+H)。
Example 6Preparation of tenofovir disoproxil (hexadecyldithiopropyl) ester (HDDSP-TFV)
1) Under anhydrous and oxygen-free conditions, a mixture consisting of 100 g of Tenofovir (TFV), 130 g of hexadecyl dithio propanol (HDDSP), 110 g of N, N, -dicyclohexyl carbodiimide and 600 ml of pyridine is stirred at 90 ℃ for 18 hours and then cooled to room temperature; filtering, leaching filter cakes by using dichloromethane, and concentrating the combined filtrate at 60 ℃ under reduced pressure to remove volatile matters;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) the layers were allowed to settle, the aqueous layer was extracted with 200 ml ethyl acetate, adjusted to pH 3 with 35% sodium hydroxide and the aqueous layer was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 190 g of tenofovir disoproxil fumarate lipid monoester (HDDSP-TFV) as a white solid.
Example 7Preparation of tenofovir disoproxil (hexadecyldithiopropyl) ester (HDDSP-TFV)
1) A mixture of 100 g Tenofovir (TFV), 20 g sodium hydroxide and 500 ml N, N-dimethylformamide was stirred at room temperature for 3 hours and concentrated at 80 ℃ under reduced pressure to remove volatiles; adding 500 ml of N, N-dimethylformamide and 155 g of hexadecyl dithiopropanol methanesulfonate (HDDSPMs), stirring at 100 ℃ for 18 hours under the protection of nitrogen, and cooling to room temperature; then, the volatile matter was removed by concentration under reduced pressure at 80 ℃;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) the layers were allowed to settle, the aqueous layer was extracted with 200 ml ethyl acetate, adjusted to pH 3 with 35% sodium hydroxide and the aqueous layer was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 188 g of tenofovir disoproxil monoester (HDDSP-TFV) as white solid.
Example 8Preparation of tenofovir disoproxil (hexadecyldithiopropyl) ester (HDDSP-TFV)
1) A mixture of 68 g of hydroxypropyl adenine (HPA), 230 g of HDDSPTs, 30 g of magnesium tert-butoxide and 500 ml of N, N-dimethylformamide was stirred at 80 ℃ for 6 hours and then concentrated under reduced pressure to remove volatiles;
2) adding 500 ml of ethyl acetate, stirring at room temperature to disperse uniformly, adding 500 ml of 3N hydrochloric acid, and continuing stirring for 30 minutes;
3) the layers were allowed to settle, the aqueous layer was extracted with 200 ml ethyl acetate, adjusted to pH 3 with 35% sodium hydroxide and the aqueous layer was extracted with dichloromethane (500 ml x 2); the dichloromethane was distilled off under reduced pressure, and 500 ml of methanol and 30 ml of dichloromethane were added to the residue;
4) stirring, heating and dissolving, slowly cooling to 0-5 ℃, and continuously stirring for 1 hour at the temperature;
5) filtering, leaching filter cakes by acetone, and drying at 50 ℃ to obtain 193 g of tenofovir disoproxil fumarate lipid monoester (HDDSP-TFV) as a white solid.
Example 9Tenofovir Mono (Hexadecyloxyethoxyethyl) ester (HDE)E-TFV) preparation of sodium salt
1) 100 g of tenofovir disoproxil (hexadecanooxyethoxyethyl) acetate (HDEE-TFV) was dissolved in a mixed solvent composed of 100 ml of methanol and 900 ml of dichloromethane with stirring at room temperature, and 30 g of 30% sodium methoxide solution in methanol was slowly added; after stirring for 1 hour, concentrating under reduced pressure at 50 deg.C to remove volatile;
2) adding 350 ml of ethanol, stirring at 60 ℃ to dissolve, adding 350 ml of acetone, and continuously stirring at room temperature for 20 hours;
3) continuously stirring for 48 hours at the temperature of 0-5 ℃, filtering, and leaching a filter cake with 200 ml of acetone;
4) decompression drying at 40 deg.c to obtain tenofovir disoproxil monoester (HDDSP-TFV) sodium salt in 99 g and white solid purity of 99.8%.
Example 10Preparation of Tenofovir mono (hexadecyl dithio propyl) ester (HDDSP-TFV) sodium salt
1) 100 g of tenofovir disoproxil (hexadecyldithiopropyl) ester (HDDSP-TFV) was dissolved in a mixed solvent composed of 100 ml of methanol and 900 ml of dichloromethane with stirring at room temperature, and 35 g of 25% sodium methoxide solution in methanol was slowly added; after stirring for 1 hour, concentrating under reduced pressure at 50 deg.C to remove volatile;
2) adding 350 ml of ethanol, stirring at 60 ℃ to dissolve, adding 350 ml of acetone, and continuously stirring at room temperature for 20 hours;
3) continuously stirring for 48 hours at the temperature of 0-5 ℃, filtering, and leaching a filter cake with 200 ml of acetone;
4) vacuum drying at 40 deg.c to obtain tenofovir disoproxil monoester (HDDSP-TFV) sodium salt in 98.7 g and white solid in 99.8% purity.
Example 11Results of oral bioavailability study
The oral bioavailability of test compounds (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) was investigated by comparison with the assay of the test compound (TFV, TDF, HDDSP-TFV) in the urine after oral and intravenous administration in mice, as disclosed in the reference (Clin. chem.1992,38,480-48; J.Med. chem.1994,37, 1857-1864).
Dissolving the compounds to be detected (TFV, TDF, TAF, HDEE-TFV and HDDSP-TFV) with dimethyl sulfoxide, and diluting the solution to the required concentration by using a phosphate buffer solution to respectively prepare the solutions of the compounds to be detected (TFV, TDF, TAF, HDEE-TFV and HDDSP-TFV) with the required concentrations.
48 BACLB/c mice weighing 20-25 g were randomly divided into four groups of 12 mice each. After fasting the mice for 12h, preparing a physiological saline solution of 15 mg/ml by using an intravenous injection solution of a compound to be detected (TFV, TDF, TAF, HDEE-TFV and HDDSP-TFV), and administering the solution by tail vein injection; the test compound (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) solution for oral administration is prepared into an aqueous solution with the concentration of 3 mg/ml and containing 5 percent of dimethyl sulfoxide for gastric lavage and administration. The intravenous and oral administration of the test compound corresponded to 30 mg/Kg of TFV.
After 48h of administration, urine of each group of mice was collected, and the content of the test compound (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) in the urine was determined.
The bioavailability of the oral administration was calculated according to the following formula and the results are shown in table 1.
Bioavailability [ M ]1]0-48h/[M2]0-48hX100％。
Wherein [ M1]0-48hThe total amount of drug excreted in urine within 48 hours after oral administration, [ M ]2]0-48hThe total amount of the drug excreted in urine within 48 hours after intravenous administration.
TABLE 1 results of oral bioavailability study
As can be seen from Table 1, HDEE-TFV, HDDSP-TFV and especially HDDSP-TFV of the present invention have better oral bioavailability than TFV, TDF, TAF.
Example 12Research on metabolism of rat liver cells into tenofovir diphosphate
1) Rat hepatocytes: male Sprague Dawley rats weighing 250-300 g of their foraging weight were selected and rat hepatocytes 20mg/ml (wet weight) and greater than 85% Trypan Blue (Trypan Blue) activity were prepared as disclosed in the reference (J.cell.biol.1969,43, 506-520; Eur.J.biochem.1982,122, 87-93);
2) buffer solution: a buffered solution of Krebs (Krebs) sodium bicarbonate containing glucose at a concentration of 20mM and Bovine Serum Albumin (BSA) at 1 mg/ml; continuously stirring for 48 hours at the temperature of 0-5 ℃, filtering, and leaching a filter cake with 200 ml of acetone;
3) aqueous acetonitrile solution: 60% acetonitrile in water containing 0.1mg/ml dicyclohexylcarbodiimide (DCCD) and 0.1% (by volume) ammonium hydroxide;
4) culturing 10 mu M of a compound to be detected (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV), 2ml of a buffer solution and rat hepatocytes for 2h at 37 ℃, wherein the compound to be detected (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) is dissolved by dimethyl sulfoxide and diluted to a required concentration by a phosphate buffer solution to prepare a solution of the compound to be detected (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) with the required concentration respectively;
5) the cell suspension obtained in step 1) was subjected to 1600. mu.l aliquots and centrifuged. Discarding the supernatant, retaining the precipitate, respectively adding 500 μ l acetonitrile water solution, and vigorously vortex and shake; 14000 rpm/min centrifugation;
6) taking the supernatant for LC-MS/MS analysis. The content of the test compound (TFV, TDF, TAF, HDEE-TFV, HDDSP-TFV) metabolized into tenofovir diphosphate in rat hepatocytes is quantitatively detected by MS/MS mode detection and compared with lamivudine-5' -triphosphate standard, and the result is shown in Table 2.
TABLE 2 study of the metabolism of the Compounds in rat hepatocytes to Tenofovir diphosphate
As can be seen from Table 2, HDEE-TFV, HDDSP-TFV and HDDSP-TFV of the present invention are more easily metabolized into the pharmaceutically active ingredient in the liver than TFV, TDF and TAF.
Example 13Investigation of anti-HBV viral Activity
The influence of the compound on the replication of hepatitis B virus and HIV in vitro is determined by adopting a cell culture method. In the research of anti-hepatitis B virus activity, the sample cytotoxicity test method comprises the following steps: the test cells were prepared into 10 ten thousand cells per ml, inoculated into a cell culture plate, 96-well plate, 100. mu.l/well, 37 ℃ and 5% CO2After 24 hours of culture, the cells were tested after growth into monolayers. The target compound and the control medicinal culture solution are prepared into required concentration, then added into a 96-hole cell culture plate, and the medicinal solution with the same concentration is added once per day for every 4 holes, and simultaneously the drug-free control group is added. And (5) observing cytopathic effect, and observing the cytopathic effect degree under a microscope for 8 days. The test method for inhibiting the activity of the hepatitis virus by the sample comprises the following steps: inoculating 10 ten thousand cells per ml into cell culture plate, 96-well plate, 100 microliter per well, 37 deg.C, 5% CO2Culturing for 24 hr, adding the medicine, setting cell control group, and changing the original concentration liquid medicine or control culture solution once in 4 days. Extracting HBV-DNA by molecular cloning experiment after cell lysis. Hybridizing each sample spot, autoradiography, measuring the A value of each hybridization point, calculating the HBV-DNA content of the cell control and administration group by using the regression equation of the standard curve, and calculating the half Effective Concentration (EC)50) The results are shown in Table 3.
TABLE 3 investigation of the anti-HBV Activity of the Compounds
As can be seen from Table 3, HDEE-TFV, HDDSP-TFV and HDDSP-TFV of the present invention have better anti-HBV virus activity than TFV, TDF and TAF.
Example 14Degrees of anti-HIV-1 Virus Activity
Adding 8 liquid medicines with different dilution concentrations and positive control liquid medicines into 96-hole cell culture, repeating 2 holes for each dilution, and setting cell control; then 2x105Cells/ml 100. mu.l were seeded in 96-well drug-containing cell culture plates. Placing at 37 ℃ and 5% CO2And culturing in a saturated humidity incubator, and observing cytopathic effect every day. According to the operation steps provided by the HIV-1P24 antigen kit, the content of HIV-1P24 antigen in cell culture supernatant on the 4 th day (96 hours) after medicine adding is measured, and the half Effective Concentration (EC) of the medicine is calculated50) The results are shown in Table 4;
TABLE 4 Degrees of the Activity of the Compounds against HIV-1 Virus
As can be seen from Table 4, HDEE-TFV, HDDSP-TFV and especially HDDSP-TFV of the present invention have better anti-HIV activity than TFV, TDF and TAF.
In conclusion, the experimental data of the embodiments 11 to 14 show that the HDEE-TFV and the HDDSP-TFV, especially the HDDSP-TFV, have better liver targeting property, bioavailability, safety and effectiveness, and further have better antiviral effect.
The embodiments of the present invention have been described above. However, the present invention is not limited to the above embodiment. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A tenofovir lipid monoester compound shown as a compound (1) or a pharmaceutically acceptable salt thereof,
wherein X is selected from O, S or SS;
when X is selected from O, s is selected from an integer of 2-10, r is selected from an integer of 2-5, and t is selected from an integer of 0-17;
when X is selected from S, S is selected from an integer of 1-10, r is selected from an integer of 2-5, and t is selected from an integer of 0-17;
when X is selected from SS, s is selected from an integer of 1-10, r is selected from 3, and t is selected from an integer of 0-17.
2. The compound of claim 1, wherein in the compound (1), X is selected from O or SS;
when X is selected from O, s is selected from an integer of 2-4, r is selected from an integer of 2-3, and t is selected from an integer of 10-15;
when X is selected from SS, s is selected from an integer of 1-4, r is selected from 3, and t is selected from an integer of 10-15.
3. The compound according to claim 1 or 2, wherein the compound (1) is selected from the group consisting of,
4. the compound of claim 1, wherein said pharmaceutically acceptable salt is selected from the group consisting of NH4Na, K, Ca or Mg salts;
preferably, the pharmaceutically acceptable salt of compound (1) is selected from the group consisting of,
5. a process for the preparation of compound (1) according to any one of claims 1 to 4, which comprises:
scheme 1:
1) chlorination: mixing Tenofovir (TFV) with a chlorination aid and a chlorinating agent, and reacting to obtain a compound (3); the chlorination auxiliary agent is HCONR1 2，R1Are the same or different and are selected from C1-6An alkyl group;
2) esterification: carrying out esterification reaction on the compound (3) and ROH, and then carrying out hydrolysis reaction in the presence of acid to obtain a compound (1);
or
Scheme 2:
reacting tenofovir with a compound (6) to obtain a compound (1);
or
Scheme 3:
reacting tenofovir with a compound (7) to obtain a compound (1);
or
Scheme 4:
reacting hydroxypropyl adenine (HPA) with a compound (8), and performing acidolysis to obtain a compound (1);
r is selected from [ (CH)2)rX]s(CH2)tCH3；
Y is selected from Cl, Br, I, MsO, TsO or TfO;
z is selected from MsO, TsO or TfO.
6. A process for preparing a pharmaceutically acceptable salt of a compound of any one of claims 1 to 4, comprising: and (3) carrying out neutralization reaction on the compound (1) and alkali to obtain a pharmaceutically acceptable salt of the compound (1).
7. Use of the compound (1) according to any one of claims 1 to 4 and/or a pharmaceutically acceptable salt thereof for the preparation of an antiviral medicament.
8. The use of claim 7, wherein the virus is hepatitis B virus and/or HIV.
9. A pharmaceutical composition comprising the compound (1) according to any one of claims 1 to 4 and/or a pharmaceutically acceptable salt thereof.
10. The pharmaceutical composition of claim 9, wherein the pharmaceutical composition is used for treating hepatitis b and/or aids.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811551187 | 2018-12-18 | ||
| CN2018115511879 | 2018-12-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110655534A true CN110655534A (en) | 2020-01-07 |
Family
ID=69028496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910257106.2A Pending CN110655534A (en) | 2018-12-18 | 2019-04-01 | Tenofovir lipid monoester compound and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110655534A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109320553A (en) * | 2017-12-21 | 2019-02-12 | 深圳市塔吉瑞生物医药有限公司 | For antiviral novel nucleoside reverse transcriptase inhibitor |
-
2019
- 2019-04-01 CN CN201910257106.2A patent/CN110655534A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109320553A (en) * | 2017-12-21 | 2019-02-12 | 深圳市塔吉瑞生物医药有限公司 | For antiviral novel nucleoside reverse transcriptase inhibitor |
Non-Patent Citations (3)
| Title |
|---|
| GIESLER, KYLE E. ET AL.: "Next-Generation Reduction Sensitive Lipid Conjugates of Tenofovir: Antiviral Activity and Mechanism of Release", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
| GIESLER, KYLE E. ET AL.: "Reduction Sensitive Lipid Conjugates of Tenofovir: Synthesis,Stability, and Antiviral Activity", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
| TOMÁŠ TICHY ET AL.: "New prodrugs of Adefovir and Cidofovir", 《BIOORGANIC & MEDICINAL CHEMISTRY》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2915381T3 (en) | nucleotide analogs | |
| KR102057751B1 (en) | Tenofovir prodrug and pharmaceutical uses thereof | |
| ES2609095T3 (en) | Nephrotoxicity reduction methods in subjects to whom nucleoside is administered | |
| US20220323476A1 (en) | Antiviral prodrugs and formulations thereof | |
| WO2006029081A2 (en) | Nucleoside-lipid conjugates, their method of preparation and uses thereof | |
| EA019883B1 (en) | Carba-nucleoside analogs for antiviral treatment | |
| CN102471248A (en) | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid | |
| JP6679624B2 (en) | Tenofovir monobenzyl ester phosphamide prodrug, process for its preparation and use | |
| CN1426418A (en) | Phosphate nucleotide compound' | |
| ES2700117T3 (en) | Derivatives of phosphonate ester and methods of synthesis thereof | |
| CN112898346B (en) | Water-soluble polycyclic compounds, pharmaceutical compositions and uses thereof | |
| ES2564144T3 (en) | 6- [2- (phosphonomethoxy) alkoxy] pyrimidine derivatives having antiviral activity | |
| CN110655534A (en) | Tenofovir lipid monoester compound and preparation method and application thereof | |
| JP6872179B2 (en) | New polycrystalline form of tenofovir prodrug and its manufacturing method and application | |
| ES2710915T3 (en) | Complex compounds of germanium, methods for the production thereof and drugs | |
| US9085593B2 (en) | Therapeutic agent for arthrosis | |
| CN110655546B (en) | Sofosbuvir derivative, and preparation method and application thereof | |
| US10307424B2 (en) | Drug with hepatoprotective activity | |
| CA2624533A1 (en) | Phosphoantigen salts of organic bases and methods for their crystallization | |
| CN110407878A (en) | Tenofovir prodrug crystal form and its preparation method and application | |
| CN108264524A (en) | Emtricitabine phosphonate compound |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 236626 zone B, Taihe Industrial Park, Fuyang City, Anhui Province Applicant after: Anhui Baker Pharmaceutical Co.,Ltd. Address before: 236626 zone B, Taihe Industrial Park, Fuyang City, Anhui Province Applicant before: ANHUI BIOCHEM UNITED PHARMACEUTICAL Co.,Ltd. |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |
|
| RJ01 | Rejection of invention patent application after publication |